medline.ch Onkologie Urologische Tumoren

conid:1879
-kaloNeDinamik-------------------------------------------jo
-session-------------------------------------------Array
(
    [ID_S] => IP: 100.24.115.215; DATE: 2022/05/18/ 12:42:24
    [tip] => 2
    [contentType] => db
    [ses_userid] => 2
    [thisMode] => 
    [level_0] => 2
    [level_1] => 15
    [level_2] => 3
    [level_3] => 0
    [level_4] => 0
    [level] => 2
    [nodetype] => 2
    [node_family_id] => 0
    [monitor] => content
    [id_contentit_from_php_file] => 1879
    [uniqueid] => 20220518124224100241152159417
    [lang] => Lng1
    [contentId] => 1879
    [browser] => IE
    [clas_css] => 0
    [level_p] => 2
    [lng] => Lng1
    [nodetype_ci] => -1
    [usr] => 0
    [vazhdopunen] => po
    [search_for] => ("urogenital neoplasms"[Majr] OR (("neoplasm"[ti] OR neoplasms[ti] OR cancer[ti] OR carcinoma[ti] OR tumor[ti] OR tumour[ti] OR "secondary"[subheading:majr]) AND (bladder[ti] OR prostatic[ti] OR prostate[ti] OR testicular[ti] OR testis[ti] OR penile[ti] OR kidney[ti] OR renal[ti]))  AND ("practice guideline" OR systematic[sb] OR "clinical trials"[mesh] OR "meta analysis"[pt] OR "epidemiologic studies"[mesh] OR randomi* OR "meta analysis" OR "evidence based" OR placebo* OR "single blind" OR "double blind" OR "control group" OR "triple blind" OR study[ti] OR studies[ti] OR trial[ti] OR trials[ti] OR consensus OR placebo OR review[pt] OR "sensitivity and specificity"[MeSH Terms] OR diagnos*[Ti] OR diagnosis[MeSH:noexp] OR diagnostic *[MeSH:noexp] OR diagnosis,differential[MeSH:noexp] OR diagnosis[Subheading:noexp] OR accuracy[Title/Abstract] OR "predictive value"[Title/Abstract]) AND (english[language] OR german[language] OR french[language] OR italian[language] OR spanish[language]) NOT (veterinary[subheading] OR "genital neoplasms, female"[mesh])
)

medline.ch

En | De

Impressum | Feedback

Sie sind hier: Onkologie » Urologische Tumoren

18. Mai 2022

Kardiovaskuläre Erkrankungen

Muskuloskelettale Erkrankungen

Gynäkologische Tumoren

Schrift:

Seite 1 von 7300


	Artikel 1 - 20 / 145996

	Circulating free testosterone and risk of aggressive prostate cancer: prospective and Mendelian randomization analyses in international consortia. Int J Cancer Watts EL, Perez-Cornago A, Fensom GK, Smith-Byrne K, Noor U, Andrews CD, Gunter MJ, Holmes MV, Martin RM, Tsilidis KK, Albanes D, Barricarte A, Bueno-de-Mesquita HB, Chen C, Cohn BA, Dimou NL, Ferrucci L, Flicker L, Freedman ND, Giles GG, Giovannucci EL, Goodman GE, Haiman CA, Hankey GJ, Huang J, Huang WY, Hurwitz LM, Kaaks R, Knekt P, Kubo T, Langseth H, Laughlin G, Le Marchand L, Luostarinen T, MacInnis RJ, Mäenpää HO, Männistö S, Metter EJ, Mikami K, Mucci LA, Olsen AW, Ozasa K, Palli D, Penney KL, Platz EA, Rissanen H, Sawada N, Schenk JM, Stattin P, Tamakoshi A, Thysell E, Tsai CJ, Tsugane S, Vatten L, Weiderpass E, Weinstein SJ, Wilkens LR, Yeap BB, PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS., Allen NE, Key TJ, Travis RC. PMID: 35579976 [PubMed - as supplied by publisher]
	Ultra-high-field MR in Prostate cancer: Feasibility and Potential. MAGMA Tenbergen CJA, Metzger GJ, Scheenen TWJ. PMID: 35579785 [PubMed - as supplied by publisher]
	[Failure patterns following external beam radiotherapy with or without additional focal boost in the randomized FLAME trial for localized prostate cancer]. Strahlenther Onkol Spohn SKB, Grosu AL. PMID: 35579679 [PubMed - as supplied by publisher]
	Recent clinical trial data of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol Beltran H. PMID: 35579578 [PubMed - as supplied by publisher]
	Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol Rettig MB, Beltran H, Oh WK. PMID: 35579577 [PubMed - as supplied by publisher]
	Pre-operative magnetic resonance imaging can predict prostate cancer with risk for positive surgical margins. Abdom Radiol (NY) Quentin M, Schimmöller L, Ullrich T, Valentin B, Demetrescu D, Al-Monajjed R, Mally D, Esposito I, Albers P, Antoch G, Arsov C. PMID: 35578110 [PubMed - as supplied by publisher]
	Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation-A Multicenter Validation Study. Eur Urol Focus Geboers B, Gondoputro W, Thompson JE, Reesink DJ, van Riel LAMJG, Zhang D, Blazevski A, Doan P, Agrawal S, Matthews J, Haynes AM, Liu Z, Delprado W, Shnier R, de Reijke TM, Lawrentschuk N, Stijns PEF, Yaxley JW, Scheltema MJ, Stricker PD. PMID: 35577751 [PubMed - as supplied by publisher]
	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum. Eur Urol Focus Beijert IJ, Hentschel AE, Bründl J, Compérat EM, Plass K, Rodríguez O, Subiela Henríquez JD, Hernández V, de la Peña E, Alemany I, Turturica D, Pisano F, Soria F, , Bauerová L, Pe, Maxim Bruins H, Runneboom W, Herdegen S, Breyer J, Brisuda A, Calatrava A, Rubio-Briones J, Seles M, Mannweiler S, Bosschieter J, Kusuma VRM, Ashabere D, Huebner N, Cotte J, Mertens LS, Masson-Lecomte A, Liedberg F, Cohen D, Lunelli L, Cussenot O, El Sheikh S, Volanis D, Côté JF, Rouprêt M, Haitel A, Shariat SF, Mostafid AH, Nieuwenhuijzen JA, Zigeuner R, Dominguez-Escrig JL, Hacek J, Zlotta AR, Burger M, Evert M, Hulsbergen-van de Kaa CA, van der Heijden AG, A L M Kiemeney L, Soukup V, Molinaro L, Gontero P, Llorente C, Algaba F, Palou J, N'Dow J, Ribal MJ, van der Kwast TH, Babjuk M, Sylvester RJ, van Rhijn BWG. PMID: 35577750 [PubMed - as supplied by publisher]
	Re: Jian Pan, Yu Wei, Tingwei Zhang, et al. Stereotactic Radiotherapy for Lesions Detected via ⁶⁸Ga-Prostate-specific Membrane Antigen and ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progression on Androgen Deprivation Therapy: A Prospective Single-center Study. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2022.02.002. Eur Urol Oncol Guler OC, Onal C. PMID: 35577749 [PubMed - as supplied by publisher]
	Physical Activity in Patients With Kidney Cancer: A Scoping Review. Clin Genitourin Cancer Arthuso FZ, Courneya KS. PMID: 35577733 [PubMed - as supplied by publisher]
	[Comparison of systematic, targeted and combined prostate biopsies for the diagnosis of prostate cancer with MRI lesion]. Prog Urol Gander J, Guandalino M, Vedrine N, Charbonnel C, Gayrel P, Ceruti F, Guy L. PMID: 35577670 [PubMed - as supplied by publisher]
	Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol Szabados B, Kockx M, Assaf ZJ, van Dam PJ, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, Pous AF, Gravis G, Herranz UA, Protheroe A, Ravaud A, Maillet D, Mendez MJ, Suarez C, Linch M, Prendergast A, Tyson C, Stanoeva D, Daelemans S, Rombouts M, Mariathasan S, Tea JS, Mousa K, Sharma S, Aleshin A, Banchereau R, Castellano D, Powles T. PMID: 35577646 [PubMed - as supplied by publisher]
	Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. Eur Urol Hall E, Hussain SA, Porta N, Lewis R, Crundwell M, Jenkins P, Rawlings C, Tremlett J, Sreenivasan T, Wallace J, Syndikus I, Sheehan D, Lydon A, Huddart R, James N, BC2001 Investigators.. PMID: 35577644 [PubMed - as supplied by publisher]
	Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial. Clin Cancer Res Lee CH, Motzer R, Emamekhoo H, Matrana M, Percent I, Hsieh JJ, Hussain A, Vaishampayan U, Liu S, McCune S, Patel V, Shaheen M, Bendell J, Fan AC, Gartrell BA, Goodman OB, Nikolinakos PG, Kalebasty AR, Zakharia Y, Zhang Z, Parmar H, Akella L, Orford K, Tannir NM. PMID: 35576438 [PubMed - as supplied by publisher]
	Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. Curr Oncol Rep Tulpule V, Morrison GJ, Falcone M, Quinn DI, Goldkorn A. PMID: 35575959 [PubMed - as supplied by publisher]
	Improved long-term outcome of patients with non-muscle invasive, low and intermediate risk bladder cancer between 1997 and 2014; a Swedish population-based study. Scand J Urol Wang EYH, Pihlström N, Malmström PU, Gårdmark T. PMID: 35575423 [PubMed - as supplied by publisher]
	Identifying homogeneous healthcare use profiles and treatment sequences by combining sequence pattern mining with care trajectory clustering in kidney cancer patients on oral anticancer drugs: A case study. Health Informatics J Baudrier C, Tran Y, Delanoy N, Katsahian S, Sabatier B, Perrin G. PMID: 35575035 [PubMed - in process]
	Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Non-muscle Invasive Bladder Cancer. J Urol Kates M, Mansour AM, Lamm DL, Shore N, Maulhardt H, Wendt A, Verco J, Marin A, Dewnani K, Verco S, diZerega GS. PMID: 35574612 [PubMed - as supplied by publisher]
	A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma. Front Oncol Jo H, Hong J, Kim H, Kim HR, Kwon GY, Kang KA, Park SY, Kim CK, Park BK, Chung JH, Song W, Kang M, Sung HH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Park SH. PMID: 35574412 [PubMed]
	Cancer/Testis Antigens as Biomarker and Target for the Diagnosis, Prognosis, and Therapy of Lung Cancer. Front Oncol Yang P, Qiao Y, Meng M, Zhou Q. PMID: 35574342 [PubMed]

Artikel 1 - 20 / 145996

Seite 1 von 7300

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung